Analysis of the Promoter-Specific Estrogenic Potency of the Phytoestrogens Genistein, Daidzein and Coumestrol

Abstract

Estrogens modulate the transcription of sensitive genes either via binding of the activated ER to responsive elements in their promoter region or via binding of the activated ER to transcription factors like NFκB. In this study we have analyzed the effects of the phytoestrogens daidzein, coumestrol and genistein in promoter-specific reporter gene systems. The dose-dependent ability to stimulate an ERE-bearing reporter in MVLN breast cancer cells was compared to the dose-dependent ability to repress the IL-1β-stimulated reporter in U2OS osteosarcoma cells. Coumestrol, daidzein and genistein stimulate the expression of the ERE-dependent reporter in MVLN cells and repress the activity of the IL-6 promoter in U2OS cells in a dose-dependent manner. Interestingly, the relative potency of all phytoestrogens to repress the activity of the IL-6 promoter in U2OS cells was much higher than their potency to stimulate the ERE-dependent reporter in MVLN cells. We assume that the demonstrated promoter-specific potency therefore could be an important mechanism to explain a tissue-specific action of some of these compounds.

References

• 1 Knight D C, Eden J A. A review of the clinical effects of phytoestrogens.  Obstet Gynecol. 1996;  87 897-904
• 2 Krishnan V, Heath H, Bryant H U. Mechanism of action of estrogens and selective estrogen receptor modulators.  Vitam Horm. 2000;  60 123-47
• 3 O’Lone R, Frith M C, Karlsson E K, Hansen U. Genomic targets of nuclear estrogen receptors.  Mol Endocrinol. 2004;  18 1859-75
• 4 McDonnell D P. The molecular determinants of estrogen receptor pharmacology.  Maturitas. 2004;  48 (Suppl 1) 7-12
• 5 McKay L I, Cidlowski J A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways.  Endocr Rev. 1999;  20 435-59
• 6 Kurebayashi S, Miyashita Y, Hirose T, Kasayama S, Akira S, Kishimoto T. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor.  J Steroid Biochem Mol Biol. 1997;  60 11-7
• 7 Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck A J. Phytoestrogens: recent developments.  Planta Med. 2003;  69 589-99
• 8 Krebs E E, Ensrud K E, MacDonald R, Wilt T J. Phytoestrogens for treatment of menopausal symptoms: a systematic review.  Obstet Gynecol. 2004;  104 824-36
• 9 Pons M, Gagne D, Nicolas J C, Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules.  Biotechniques. 1990;  9 450-9
• 10 Demirpence E, Duchesne M J, Badia E, Gagne D, Pons M. MVLN cells: a bioluminescent MCE-7-derived cell line to study the modulation of estrogenic activity.  Steroid Biochem Mol Biol. 1993;  46 355-64
• 11 Pottratz S T, Bellido T, Mocharla H, Crabb D, Manolagas S C. 17beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.  J Clin Invest. 1994;  93 944-50
• 12 Tora L, White J, Brou C, Tasset D, Webster N, Scheer E. et al . The human estrogen receptor has two independent nonacidic transcriptional activation functions.  Cell. 1989;  59 477-87